Press release
7 January 2022
Cellular Goods PLC
("Cellular Goods" or "the Company")
Results of Annual General Meeting
Cellular Goods (LSE: CBX), a UK-based provider of premium consumer products based on lab-made cannabinoids, is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed.
A shareholders' Q&A has been posted here:
https://www.cellulargoods.co/investors/shareholder-documents
For further information please contact:
| Cellular Goods | |
| Anna Chokina Chief Executive Neil Thapar Investor Relations | via Tancredi +44 207 887 7633
+44 787 645 5323 |
| Tennyson Securities | |
| Corporate Broker Peter Krens |
+44 207 186 9030 |
| Novum Securities | |
| Corporate Broker Colin Rowbury Jon Belliss |
+44 207 399 9427 |
| Tancredi Intelligent Communication | |
| Media Relations Helen Humphrey Edward Daly Charlie Hobbs Salamander Davoudi |
+44 744 922 6720 +44 786 143 0057 +44 789 755 7112 +44 795 754 9906 |
About Cellular Goods PLC:
Cellular Goods is a UK-based provider of premium consumer products based on lab-made cannabinoids. It was established in August 2018 to develop efficacy-led and research-backed cannabinoid products. The initial focus is on three product verticals: premium CBG skincare and CBD ingestible and topical athletic recovery products, with the first products launched in December 2021 initially through the Company's website. The Company's shares are listed on the main market of the London Stock Exchange.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
